Bencherif Merouane 4

4 · TARGACEPT INC · Filed Jan 20, 2011

Form 4

Period: 2011-01-18

VP, Preclinical Research

Transactions

Exercise/Conversion
Common Stock
2011-01-18$5.55/sh+22,800$126,540→ 22,800 total
Sale
Common Stock
2011-01-19$27.09/sh−30,203$818,257→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
2011-01-19−7,951→ 0 total
Exercise: $5.55Exp: 2016-08-15→ Common Stock (7,951 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2011-01-19−22,252→ 0 total
Exercise: $1.75Exp: 2013-10-30→ Common Stock (22,252 underlying)
Exercise/Conversion
Common Stock
2011-01-19$5.55/sh+7,951$44,128→ 7,951 total
Sale
Common Stock
2011-01-18$27.17/sh−22,800$619,476→ 0 total
Exercise/Conversion
Common Stock
2011-01-19$1.75/sh+22,252$38,941→ 30,203 total
Exercise/Conversion
Stock Option (Right to Buy)
2011-01-18−22,800→ 7,951 total
Exercise: $5.55Exp: 2016-08-15→ Common Stock (22,800 underlying)

Footnotes (4)

[F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.94 to $27.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.69 to $27.44, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]This option vested in installments and became vested and exercisable in full on June 30, 2010.
[F4]This option vested in installments and became vested and exercisable in full on September 30, 2007.

Documents

1 file